Galectin Therapeutics converts $105.8M debt to equity, eliminating all outstanding notes from Chairman Uihlein

GALECTIN THERAPEUTICS INC

Converted $91.0M principal + $14.8M accrued interest ($105.8M total) into 34,376,167 shares at ~$3.07 blended price.
Post-conversion shares outstanding: 100,849,644; Uihlein owns ~44.3% voting power (49.3% including warrants).
Sixth $10M credit facility (Dec 2025) remains undrawn and available; no notes issued under it.
Company must register resale of shares within 180 days per registration rights provisions.
CEO says conversion 'transformative' for balance sheet, strengthens ability to advance belapectin program.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.